Literature DB >> 8980397

Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.

M A Izquierdo1, J J Neefjes, A E Mathari, M J Flens, G L Scheffer, R J Scheper.   

Abstract

Multidrug resistance (MDR) to anti-cancer drugs has been associated with the overexpression of P-glycoprotein (P-gp) and the multidrug resistance-associated protein (MRP), both being members of the ATP-binding cassette (ABC) superfamily of transporters. We investigated whether in addition to P-gp and MRP, another ABC transporter, the transporter associated with antigen processing (TAP), is associated with MDR. TAP plays a major role in MHC class I-restricted antigen presentation by mediating peptide translocation over the endoplasmic reticulum membrane. TAP1 and P-gp share a significant degree of homology among their transmembrane domains, which are thought to be the primary determinants of substrate specificity, and both can apparently mediate the translocation of peptides. Using immunocytochemistry and Western blot, TAP was overexpressed in parallel with MHC class I in several MDR human cancer cell lines. TAP was overexpressed more frequently in MRP-positive MDR cell lines (three out of three) than in P-gp positive MDR cells (two out of five). Reversal of resistance resulted in a decrease in TAP levels. Transfection of the TAP genes into TAP-deficient lymphoblastoid T2 cells conferred mild resistance to etoposide, vincristine and doxorubicin (2- to 2.5-fold). Furthermore, etoposide and vincristine inhibited TAP-dependent peptide translocation to the endoplasmic reticulum. Collectively, our results suggest that TAP may modestly contribute to the MDR phenotype, in particular in MRP- overexpressing MDR cells. Further insight into the role of TAP in MDR will require the study of other transfectants, as well as the investigation of TAP expression in P-gp and MRP-negative MDR cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980397      PMCID: PMC2074820          DOI: 10.1038/bjc.1996.660

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Peptide transport by the multidrug resistance pump.

Authors:  R C Sharma; S Inoue; J Roitelman; R T Schimke; R D Simoni
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

2.  Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.

Authors:  F Momburg; V Ortiz-Navarrete; J Neefjes; E Goulmy; Y van de Wal; H Spits; S J Powis; G W Butcher; J C Howard; P Walden
Journal:  Nature       Date:  1992-11-12       Impact factor: 49.962

3.  Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells.

Authors:  D Marquardt; M S Center
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

4.  Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection.

Authors:  B C Guild; R C Mulligan; P Gros; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

6.  Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association.

Authors:  J J Neefjes; H L Ploegh
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

7.  Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

8.  Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance.

Authors:  R J Scheper; J W Bulte; J G Brakkee; J J Quak; E van der Schoot; A J Balm; C J Meijer; H J Broxterman; C M Kuiper; J Lankelma
Journal:  Int J Cancer       Date:  1988-09-15       Impact factor: 7.396

9.  Overexpression of the cystic fibrosis transmembrane conductance regulator in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype.

Authors:  L Y Wei; M J Stutts; M M Hoffman; P D Roepe
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

10.  Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.

Authors:  G J Schuurhuis; H J Broxterman; J H de Lange; H M Pinedo; T H van Heijningen; C M Kuiper; G L Scheffer; R J Scheper; C K van Kalken; J P Baak
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  9 in total

1.  Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.

Authors:  Thititip Tippayamontri; Rami Kotb; Benoit Paquette; Léon Sanche
Journal:  Invest New Drugs       Date:  2010-07-24       Impact factor: 3.850

2.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

3.  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Mol Cancer       Date:  2010-12-15       Impact factor: 27.401

4.  Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines.

Authors:  G M O'Neill; G B Peters; R M Harvie; H B MacKenzie; S Henness; R A Davey
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

5.  Recipients with in utero induction of tolerance upregulated MHC class I in the engrafted donor skin.

Authors:  Jeng-Chang Chen; Liang-Shiou Ou; Hsiu-Yueh Yu; Ming-Ling Kuo; Pei-Yeh Chang; Hsueh-Ling Chang
Journal:  Dis Markers       Date:  2014-07-20       Impact factor: 3.434

6.  RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.

Authors:  Dongwei Mao; Jianhua Che; Shiyu Han; Honghui Zhao; Yumei Zhu; Hong Zhu
Journal:  Mol Med Rep       Date:  2015-08-21       Impact factor: 2.952

Review 7.  Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.

Authors:  Maurice Zandvliet; Erik Teske
Journal:  Vet Sci       Date:  2015-08-12

8.  Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Authors:  G L Scheffer; M C de Jong; A Monks; M J Flens; C D Hose; M A Izquierdo; R H Shoemaker; R J Scheper
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

9.  Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.

Authors:  Anika Tabassum; Rahat Alam; Md Nazmus Samdani; Tarak Chandra Dhali; Foysal Ahammad; Abdus Samad; Tomasz M Karpiński
Journal:  J Mol Med (Berl)       Date:  2021-05-28       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.